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Recommended vaccine 
formulation
The following strains have been recommended by 
the World Health Organization (WHO) for the 2015 
Southern Hemisphere influenza season: 
• an A/California/7/2009 (H1N1)pdm09-like virus
• an A/Switzerland/9715293/2013 (H3N2)-like virus (A/South Aus-
tralia/55/2014, A/Norway/466/2014 and A/Stockholm/6/2014 are 
A/Switzerland/9715293/2013-like viruses)
• a B/Phuket/3073/2013-like virus. 
Vaccines should contain 15 μg of each haemagglutinin antigen in 
each 0.5 ml dose. 
Indications
• Pregnant women irrespective of stage of pregnancy, or postpartum 
(within 2 weeks after delivery)
• Persons (adults or children) who are at high risk for influenza 
and its complications because of underlying medical conditions 
and who are receiving regular medical care for conditions such as 
chronic pulmonary (including tuberculosis) and cardiac diseases, 
chronic renal diseases, diabetes mellitus and similar metabolic 
disorders, individuals who are immunosuppressed (including HIV 
infected persons), and individuals who are morbidly obese (body 
mass index ≥40 kg/m2)
• Healthcare workers
• Residents of old-age homes and chronic care and rehabilitation 
institutions
• Persons aged >65 years
• Children aged 6 months - 59 months 
• Persons aged 6 months to ≤18 years on long-term aspirin therapy
• Adults and children who are family contacts of high-risk cases
• Any persons wishing to minimise the risk of influenza acquisition, 
especially in industrial settings, where large-scale absenteeism 
could cause significant economic losses.
Older people, children aged <2 years and severely immuno-
compromised individuals often have lower protective immune 
response to trivalent influenza vaccines compared with younger 
healthy adults. However, even for these people influenza vaccine still 
provides some protection.
Dosage
• Adults: Whole or split-product or subunit vaccine: one dose 
intramuscularly (IM)
• Children (<12 years): Split-product or subunit vaccine: one dose IM
• Children (6 months - 8 years) who have never been vaccinated or 
when vaccine status is unknown: two doses, 1 month apart
• Children (6 months - 8 years) who have received two or more 
doses of seasonal influenza vaccine since March 2010 should 
receive one dose
• Children <3 years of age should receive half the adult dose on two 
occasions separated 1 month apart
• Influenza vaccine is not recommended for infants <6 months of 
age.
Contraindications
Persons with a history of severe (anaphylactic) hypersensitivity to any 
components of the vaccine including egg protein, or after previous 
dose of any influenza vaccine.
Precautions
• Persons with moderate illness with or without fever should 
preferably be immunised after symptoms have disappeared.
• History of Guillain-Barré syndrome within 6 weeks of receipt of 
influenza vaccine.
Timing
Vaccines should be given sufficiently early to provide protection for the 
winter. A protective antibody response takes about 2 weeks to develop.
Antiviral chemotherapy
At present influenza A(H1N1)pdm09, A(H3N2) and B viruses remain 
sensitive to oseltamivir and zanamivir. A small proportion of A(H1N1)
pdm09 viruses with highly reduced inhibition (HRI) by oseltamivir 
have been detected globally. High levels of resistance to adamantanes 
among influenza A viruses have been detected in a number of 
countries. The use of amantadine and rimantadine in the treatment of 
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influenza is therefore not recommended. The 
dosages for treatment with oseltamivir and 
zanamivir are provided in Table 1.
Antiviral 
chemoprophylaxis
Annual influenza vaccine is the best way to 
prevent influenza, because it can be given 
in advance before the possible exposures 
to the influenza viruses occur and it 
can provide safe and effective immunity 
throughout the influenza season. Antiviral 
chemoprophylaxis for contacts of persons 
with influenza is currently not recommended. 
WHO recommendations advise presumptive 
treatment using the treatment regimen 
described below, for a duration of 7 days, 
for higher-risk (patients with severe 
immunosuppression or transplant patients) 
individuals exposed to influenza instead 
of the previously recommended long-term 
lower-dose chemoprophylaxis regimen. 
These higher-risk individuals need to be 
carefully monitored during the influenza 
season for early signs of influenza and 
should be treated immediately on suspicion 
of infection.
For a more detailed description of antiviral 
management and chemoprophylaxis of 
influenza, please refer to the Healthcare 
Workers Handbook on influenza on the 
NICD website http://www.nicd.ac.za/
assets/files/Healthcare%20Workers%20
Handbook%20on%20Influenza%20in%20
SA%20_12%20May%202014%281%29.pdf 
For the full report on recommended 
influenza vaccine, refer to the WHO 
website http://www.who.int/influenza/
vaccines/virus/recommendations/201409_
recommendation.pdf?ua=1
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Table 1. Recommended dosage of antiviral agents for treatment
Age group Weight (kg) Oseltamivir dosage* Zanamivir dosage*
Adults 75 mg twice per day Two 5 mg inhalations 
(10 mg total) twice per day 
Premature neonates†
<38 weeks 1 mg/kg twice per day
38 - 40 weeks 1.5 mg/kg twice per day
Infants (14 days - 12 
months)
3 mg/kg twice a day
Children ≤15 kg 30 mg twice per day Two 5 mg inhalations 
(10 mg total) twice per day 
(only in children aged ≥7 
years)
>15 - 23 kg 45 mg twice per day 
>23 - 40 kg 60 mg twice per day 
>40 kg 75 mg twice per day 
*Recommended duration of treatment is 5 days. Zanamivir is recommended for treatment in children ≥7 years of age.
†Corrected gestational age.
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